Hoge Stephen 4: 111,679 shares of MRNA ($2,138,652)

Our Take

→Stephen Hoge's $2.1M option exercise represents a routine wealth-building transaction for Moderna's President rather than a strategic signal—the typical cadence for senior executives managing tax-efficient equity compensation. The more relevant indicator is Moderna's broader executive trading pattern: heavy option exercises amid a company struggling to diversify beyond its COVID franchise, where pipeline depth and clinical progress matter far more than insider transactions for validating turnaround credibility.